About this trial
Percutaneous CT guided biopsy is a well-established, standard sampling technique for suspected neoplastic lesions located in peripheral region in lung parenchyma. Inconclusive results on CT guided biopsy is substantially higher in large lung lesions which are prone to cause peripheral pneumonia, atelectasis and even regional necrosis, which are hard to be distinguished from tumor on CT images.
Functional imaging guided biopsy like PET/CT guided biopsy identifies areas of highest concentration of neoplastic cells and provides accurate results. Only a few studies have been done regarding PET/CT guided biopsy and studies omparing PET/CT guided and CT guided percutaneous transthoracic lung biopsy are very few and this study would be a randomized trial comparing these diagnostic modalities in terms of diagnostic yield, diagnostic accuracy of sample and complications.
Eligibility criteria
Qualifiers
Age above 18 years
INR < 1.2 and platelet counts > 80,000/mm3
CT thorax with lung lesion more than 10 mm.
Accessible lesions for CT-guided biopsy.
Disqualifiers
Participants with pre-existing bleeding diathesis like hemophilia, coagulopathy defined by -INR ≥1.2 and Platelet counts ≤ 80,000/mm3
Participants who refuse to provide consent
Signs of hypoperfusion like hypotension, cyanosis etc.
Presence of hypoxemia with SpO2 < 94 %- measured in a pulse oximeter)
Trial design
Treatments tested in this trial
- PET-CT guided biopsy
- CT guided biopsy